弥合FDA批准儿童神经调节器械的差距
Ammar Shaikhouni1,2, Cameron Brandon2, Cory Criss3
1Division of Pediatric Neurosurgery, Nationwide Children's Hospital, 700 Children's Dr., Columbus, OH 43205, USA.
Children (Basel, Switzerland)
|February 26, 2025
概括
儿科神经调节器件面临着FDA批准的重大障碍,包括道德和财务挑战. 解决这些障碍对于扩大患有神经疾病的儿童获得重要治疗的机会至关重要.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 监管科学 监管科学
背景情况:
- 神经调节装置为神经疾病提供先进的治疗方法.
- 目前FDA批准的设备主要适用于成年人群,为儿科患者留下了一个空白.
- 对成人设备的非标签使用在儿童中很常见,这突出了未满足的需求.
研究的目的:
- 审查阻碍儿童使用神经调制器械的开发和FDA批准的障碍.
- 检查影响儿科设备创新的伦理问题,小试验人群和财务阻碍因素.
- 讨论目前的倡议和监管途径,旨在促进儿科设备的访问.
主要方法:
- 关于儿科神经调节器件开发现有研究的文献综述.
- 对儿童医疗器械相关的FDA法规和批准途径的分析.
- 审查当前的FDA倡议和支持联盟.
主要成果:
- 存在重大障碍,包括道德考虑,有限的儿科试验参与者和市场规模限制.
- 成人设备的非标签使用普遍存在,这表明急需为儿科特定解决方案.
- 美国食品和药物管理局的倡议和项目,如人道主义设备豁免和现实世界证据,在应对这些挑战方面表现有前途.
结论:
- 克服监管和财务障碍对于推进儿科神经调节至关重要.
- 简化审批途径和专门的倡议可以改善儿童获得有效治疗的机会.
- 解决这些未满足的需求将提高儿童神经疾病的患者护理和治疗结果.
更多相关视频
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
3.5K
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
2.5K
相关概念视频
Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
